Evidence map›Paper›PMID 31161598›Full record

ArticleNeurotoxicity research2019

Antiproliferative Effect of Elastin-Derived Peptide VGVAPG on SH-SY5Y Neuroblastoma Cells.

Konrad A Szychowski, Agnieszka Rombel-Bryzek, Agnieszka Dołhańczuk-Śródka, Jan Gmiński

Open access · hybridAbstract read
In one paragraph

Article in Neurotoxicity research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Konrad A SzychowskiDepartment of Clinical Biochemistry and Laboratory Diagnostics, Institute of Medicine, University of Opole, Oleska 48, 45-052, Opole, Poland. konrad.szychowski@gmail.com.ORCID http://orcid.org/0000-0003-2207-1160
Agnieszka Rombel-BryzekDepartment of Clinical Biochemistry and Laboratory Diagnostics, Institute of Medicine, University of Opole, Oleska 48, 45-052, Opole, Poland.
Agnieszka Dołhańczuk-ŚródkaInstitute of Biotechnology, University of Opole, Kard. B. Kominka 6a, 45-032, Opole, Poland.
Jan GmińskiDepartment of Public Health, Dietetics and Lifestyle Disorders, Faculty of Medicine, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225, Rzeszow, Poland.
University of Opole · PLUniversity of Information Technology and Management in Rzeszow · PL

Funding

University of Information Technology and Management in Rzeszow DS 503-07-02-21University of Opole DS 6/KBB/18
6 · The paper itself

Abstract

Throughout the lifetime of humans, the amount of stem cells and the rate of cell proliferation continue to decrease. Reactive oxygen species (ROS) are one among the many factors that promote stem cell aging. Both a decrease in the level of stem cells and increase in ROS production can lead to the development of different neurodegenerative diseases. This study was conducted to determine how the VGVAPG peptide, liberated from elastin during the aging process and under pathological conditions, affects ROS production and activities of antioxidant enzymes in undifferentiated, proliferating SH-SY5Y cells. SH-SY5Y cells were maintained in Dulbecco's modified Eagle's medium/nutrient mixture F-12 supplemented with 10% heat-inactivated fetal bovine serum (FBS). After treating the SH-SY5Y cells with VGVAPG peptide, we measured ROS production; cell metabolism, proliferation, and expression; and activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT). We demonstrated that the VGVAPG peptide increases GPx expression and activity, whereas it decreases CAT expression in SH-SY5Y cells. Silencing of the GLB1 gene prevents changes in GPx activity. Despite the fact that the VGVAPG peptide increases GPx expression, it increases the ROS level. Moreover, the VGVAPG peptide decreases SH-SY5Y proliferation, which is prevented by the ROS scavenger N-acetyl-L-cysteine. Our data suggest that ROS production and decreased proliferation of SH-SY5Y cells are the results of excitotoxicity meditated through close unrecognized molecular pathways. More research is needed to elucidate the unknown mechanism of action of VGVAPG peptide in the nervous system.

Indexed as

CatalaseCell Line, TumorCell ProliferationDose-Response Relationship, DrugElastinEnzyme-Linked Immunosorbent AssayGlutathione PeroxidaseHumansKi-67 AntigenNeuroblastomaOligopeptidesPPAR gammaReactive Oxygen SpeciesReal-Time Polymerase Chain ReactionSuperoxide Dismutase-1CatalaseElastinGlutathione PeroxidaseKi-67 AntigenMKI67 protein, humanOligopeptidesPPAR gammaReactive Oxygen SpeciesSOD1 protein, humanSuperoxide Dismutase-1valyl-glycyl-valyl-alanyl-prolyl-glycineElastin-derived peptidesProliferationROSSH-SY5YVGVAPG

Identifiers

PMID31161598
PMCPMC6745029
OpenAlexW2948787913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.